The effectiveness of nicotine replacement therapy labels in helping consumers determine the most appropriate treatment could be a key factor in whether FDA allows expanded indications for the products.
FDA Asks For Road Map To Broader NRT Indications
While the agency appears to favor moving to a broad harm reduction framework for indications for NRTs, including lifting limits on recommended duration of use, there remains “a lot of devil in the details” of expanding indications.